Table 2.
Cross-sectional demographics and clinical characteristics of the studied population based on the Ptau/Aβ1-42 ratio score
| Ptau/Aβ + (n=36) | Ptau/Aβ – (n=64) | p | |
|---|---|---|---|
| Ptau/Abeta42 ratio | 0.04 (0.012) | 0.01 (0.003) | |
| Aβ level (mean, SD) | 685.2 (163.7) | 1494.2 (401.9) | |
| Sex (male/female) | 26/10 | 36/28 | 0.166 |
| BMI (mean, SD) | 26.2 (3.8) | 25.3 (3.7) | 0.338 |
| Age (years, mean, SD | 73.8 (4.9) | 72.0 (4.4) | 0.039 |
| APOE ε4 carrier (n, %) | 18 (50%) | 14 (22.6%) | 0.001 |
| MMSE (mean, SD) | 28.5 (1.5) | 28.8 (1.4) | 0.314 |
| CDR (mean, SD) | 0 (0) | 0 (0) | |
| GFAP pg/mL (mean, SD) | 211.8 ± 97.6 | 138.8 ± 49.9 | <0.001 |
| YKL-40 pg/mL (mean, SD) |
N=38 87038.7 ± 74252.3 |
N=145 60583.7 ± 54067.1 |
0.012 |
| MCP-1 pg/mL (mean, SD) |
N=34 92.6 ± 18.4 |
N=64 96.4 ± 30.7 |
0.602 |
| Eotaxin-1 pg/mL (mean, SD) |
N=34 193.6 ± 62.9 |
N=64 202.5 ± 86.7 |
0.630 |
P values in bold font were considered significant (p<0.05). Independent T-test, Pearson chi-square test, and Mann-Whitney tests were applied as appropriate